Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

11.50 +0.03 (+0.23%)
Streaming Delayed Price Updated: 2:24 PM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,584
Open 11.30
Bid (Size) 9.000 (200)
Ask (Size) 11.50 (100)
Prev. Close 11.47
Today's Range 11.30 - 11.50
52wk Range 6.340 - 76.00
Shares Outstanding 34,422,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
From MiNK Therapeutics
Via GlobeNewswire

Performance

YTD
+3.4%
+3.4%
1 Month
-10.0%
-10.0%
3 Month
+3.0%
+3.0%
6 Month
-28.1%
-28.1%
1 Year
+19.0%
+19.0%

More News

Read More
News headline image
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Earnings Scheduled For August 14, 2025 ↗
Via Benzinga
News headline image
MiNK Therapeutics (INKT) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics's Earnings Outlook ↗
Via Benzinga
News headline image
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Earnings Scheduled For November 14, 2025 ↗
Via Benzinga
News headline image
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Extends Cash Runway ↗
Via The Motley Fool
News headline image
MiNK INKT Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MiNK Therapeutics Inc (NASDAQ:INKT) Reports Wider Q2 2025 Loss, Advances Clinical Pipeline Amid Market Caution ↗
Via Chartmill
Topics Earnings
News headline image
MiNK Therapeutics Cuts Q2 Cash Use 31% ↗
Via The Motley Fool
News headline image
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
What is the current price of MiNK Therapeutics, Inc. - Common Stock?
The current price of MiNK Therapeutics, Inc. - Common Stock is 11.50
When was MiNK Therapeutics, Inc. - Common Stock last traded?
The last trade of MiNK Therapeutics, Inc. - Common Stock was at 02/25/26 02:24 PM ET
What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?
The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 395.73M
How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?
MiNK Therapeutics, Inc. - Common Stock has 396M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.